Results 171 to 180 of about 28,292 (266)

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1934-1941, August 2026.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

Plant Terpenoids in Cardioprotection: An Overview of Their Therapeutic Potential. [PDF]

Curr Issues Mol Biol
Ríos-López JL, Blanco-Salas J, Cumplido-Laso G, Hortigón-Vinagre MP.   +3 more
europepmc   +1 more source

Targeted Anti‐IL‐1 Immunomodulatory Therapy in Pediatric Onset PPP1R13L‐Related Arrhythmogenic Cardiomyopathy

American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1807-1813, August 2026.
ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg, Savannah Coppersmith, Owen Merritt, Amer Heider, Adam Helms, Thomas Michniacki, Jack Luxford, Sarah Josephi‐Taylor, Philip Roberts, Joshua Meisner   +9 more
wiley   +1 more source

Ebstein's anomaly with life-threatening arrhythmia: an unusual cardiovascular manifestation of Williams syndrome - a case report. [PDF]

BMC Cardiovasc Disord
Schouw ME, Koopmann TT, Blom NA, Stöger JL, Barge-Schaapveld DQCM, Bökenkamp R.   +5 more
europepmc   +1 more source

[Lidocaine as an anti-arrhythmia agent].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1969
openaire   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2937-2948, August 2026.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

QT-related adverse events with ondansetron and olanzapine: a real-world FAERS analysis with implications for oncology anti-emetic practice. [PDF]

Front Pharmacol
Gandhi A, Parhizgar A, Bhise V.
europepmc   +1 more source

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source

Electrocardiographic manifestations and targeted management of cardiac complications in cardiac-involved DLBCL: a retrospective case series. [PDF]

Cardiooncology
Chuang JY, Chen KT, Lin J, Lim KH, Sung MT.   +4 more
europepmc   +1 more source

Unveiling the Microvasculature: The Index of Microcirculatory Resistance and Its Expanding Role in Cardiovascular Care

Catheterization and Cardiovascular Interventions, Volume 108, Issue 2, Page 287-300, August 1, 2026.
ABSTRACT Index of microcirculatory resistance (IMR) is a cutting‐edge, wire‐based tool that advances the capability assessment of coronary microvascular function. By utilizing distal coronary pressure and mean transit time under maximal hyperemia, IMR delivers consistent, reproducible insights into the microvasculature's dynamic health.
Joanna Sohn, Matthew A. Soderstrom, Ariana Ramirez, John‐Henry Dean, Raj Shah, Debanshu Roy, Kenneth Stone, Ariel Vinas, Bryan Ramsey, Charles Lin, Robert Chilton   +10 more
wiley   +1 more source